
Tuesday, January 05, 2021 8:59:36 PM

Liked By
Spread the love. Be the first to like this post!
Recent INMB News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/15/2023 08:04:01 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/03/2023 09:48:34 PM
- INmune Bio, Inc. Announces 2022 Results and Provides Business Update • GlobeNewswire Inc. • 03/02/2023 09:05:52 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/22/2023 09:01:19 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/22/2023 09:01:14 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/21/2023 09:10:30 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/21/2023 09:08:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/21/2023 09:07:10 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/21/2023 09:05:33 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/21/2023 09:04:23 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/21/2023 09:03:19 PM
- INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2 • GlobeNewswire Inc. • 02/21/2023 02:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/10/2023 11:11:19 AM
- INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom • GlobeNewswire Inc. • 02/08/2023 01:45:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/25/2023 02:08:03 PM
- INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 01/25/2023 12:45:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/22/2022 09:01:20 PM
- INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease • GlobeNewswire Inc. • 12/22/2022 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/12/2022 10:04:48 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/09/2022 09:01:51 PM
- Maxim Group Keeps Their Buy Rating on Inmune Bio (INMB) • TipRanks • 12/09/2022 06:55:06 PM
- INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™ • GlobeNewswire Inc. • 12/08/2022 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/07/2022 09:02:30 PM
- INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer • GlobeNewswire Inc. • 12/06/2022 09:00:00 PM
- INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments • GlobeNewswire Inc. • 11/29/2022 01:00:00 PM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM